To help address platelet shortages and streamline blood center operations, The Blood Center in New Orleans has become the ...

The EMA has recommended a first-in-class Bruton’s tyrosine kinase inhibitor to treat immune thrombocytopenia in adults who are refractory to other treatments.

Hospitals and blood centers are always trying to avoid shortages. Someone needs blood every two seconds, and less than 10% of ...

After months of putting off a blood draw, Austin hairdresser encouraged by client to get test for leukemia after months of ...

Classical hematologist Srila Gopal, MD, tackles the unique complexities of treating and researching sickle cell disease and thalassemia.

This story was originally published on MedTech Dive. To receive daily news and insights, subscribe to our free daily MedTech Dive newsletter. BD has expanded a Class I Alaris recall to cover 15 ...

Credit: Getty Images CHEST has released 2 new practice guidelines on transfusions in critically ill adults that promote a more restrictive approach to RBC, FFP, and platelet transfusions. Both sets of ...

Platelet transfusion thresholds in according bleeding risk and the presence of bleeding. WHO = World Health Organization. “In practice, we see all too often [that] prophylactic transfusion of ...

Platelets (also called thrombocytes) are small blood cell fragments made by your bone marrow. They help form blood clots to stop you from bleeding when you've been injured. Platelets are small cell ...

SOMERVILLE, Mass.--(BUSINESS WIRE)-- bluebird bio, Inc. (Nasdaq: BLUE) today announced that new and updated data from its lentiviral vector (LVV) gene addition programs in patients with sickle cell ...

An investigational anti-CD38 monoclonal antibody (CM313) rapidly increased platelets in immune thrombocytopenia (ITP) patients to levels sufficient for preventing bleeding, a small single-arm Chinese ...

SOMERVILLE, Mass.--(BUSINESS WIRE)-- bluebird bio, Inc. (NASDAQ: BLUE) (“bluebird bio”) today announced it has signed its first Medicaid outcomes-based agreement for LYFGENIA™ (lovotibeglogene ...